Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.

[1]  Development of a baseline prognostic cytokine signature that correlates with nivolumab (NIVO) clearance (CL): Translational pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with renal cell carcinoma (RCC). , 2019, Journal of Clinical Oncology.

[2]  Y. Vugmeyster,et al.  Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma , 2019, CPT: pharmacometrics & systems pharmacology.

[3]  S. Sleijfer,et al.  Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer. , 2019, European journal of cancer.

[4]  A. Markham,et al.  Cemiplimab: First Global Approval , 2018, Drugs.

[5]  C. Garbe,et al.  Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Riess,et al.  Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance , 2018, Clinical Cancer Research.

[7]  E. Chartash,et al.  A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation. , 2018 .

[8]  A. Gupta,et al.  Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status , 2018, Clinical pharmacology and therapeutics.

[9]  M. Donia,et al.  Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab , 2018, Oncoimmunology.

[10]  Brett Fleisher,et al.  A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring , 2017, OncoTargets and therapy.

[11]  B. Geoerger,et al.  Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. , 2017, European journal of cancer.

[12]  S. Agrawal,et al.  Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[13]  P. Statkevich,et al.  Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma , 2017, Journal of clinical pharmacology.

[14]  R Bruno,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma , 2017, Clinical pharmacology and therapeutics.

[15]  Yahiya Y. Syed.  Durvalumab: First Global Approval , 2017, Drugs.

[16]  N. Reinmuth,et al.  Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. , 2017, Cancer treatment reviews.

[17]  Jiang Liu,et al.  Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response , 2017, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  X. Zhao,et al.  Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  D. D. de Alwis,et al.  Evaluation of dosing strategy for pembrolizumab for oncology indications , 2017, Journal of Immunotherapy for Cancer.

[20]  E. Kohn,et al.  Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Schlom,et al.  Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. , 2017, The Lancet. Oncology.

[22]  Y. Wang,et al.  Association of Time‐Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis , 2017, Clinical pharmacology and therapeutics.

[23]  D. Schadendorf,et al.  Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. , 2017, The Lancet. Oncology.

[24]  Esther S. Kim,et al.  Avelumab: First Global Approval , 2017, Drugs.

[25]  S. Agrawal,et al.  Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors , 2017, Journal of clinical pharmacology.

[26]  S. Elsamra,et al.  Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma , 2017, Expert opinion on drug metabolism & toxicology.

[27]  S. Agrawal,et al.  Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors , 2016, CPT: pharmacometrics & systems pharmacology.

[28]  S. Agrawal,et al.  Quantitative Characterization of the Exposure–Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma , 2016, CPT: pharmacometrics & systems pharmacology.

[29]  Manash S. Chatterjee,et al.  Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma , 2016, CPT: pharmacometrics & systems pharmacology.

[30]  J. Stone,et al.  Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors , 2016, CPT: pharmacometrics & systems pharmacology.

[31]  S. Kang,et al.  Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial , 2016, CPT: pharmacometrics & systems pharmacology.

[32]  K. Tewari,et al.  Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma , 2016, Expert opinion on drug metabolism & toxicology.

[33]  M. Vugt,et al.  Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010. , 2016 .

[34]  Melissa L. Johnson,et al.  A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT). , 2016 .

[35]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[36]  J. Schlom,et al.  A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses , 2016, Clinical & translational immunology.

[37]  H. Koeppen,et al.  Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor , 2016, mAbs.

[38]  S. Agrawal,et al.  Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy , 2015, Journal of Immunotherapy for Cancer.

[39]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[40]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[41]  J. Schlom,et al.  Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors. , 2015 .

[42]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[43]  V. Bedian,et al.  Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody , 2015, Cancer Immunology Research.

[44]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[45]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[46]  E. Wang,et al.  Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma , 2014, Journal of clinical pharmacology.

[47]  D. Berman,et al.  Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma , 2014, British journal of clinical pharmacology.

[48]  J. Weber,et al.  Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma , 2013, Clinical Cancer Research.

[49]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[50]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[51]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  P. LoRusso,et al.  Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells , 2010, Clinical Cancer Research.

[53]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[54]  S. O’Day,et al.  Phase I/II study of ipilimumab for patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  A. Ribas.  Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). , 2008, The oncologist.

[56]  E. Small,et al.  A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.

[57]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.